.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Baxter
Deloitte
Fish and Richardson
Argus Health
McKinsey
Fuji
Mallinckrodt
Medtronic
Novartis

Generated: July 23, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 018671

« Back to Dashboard
NDA 018671 describes SODIUM IODIDE I 123, which is a drug marketed by Mallinkrodt Nuclear, Ge Healthcare, and Cardinal Health 418, and is included in four NDAs. It is available from two suppliers. Additional details are available on the SODIUM IODIDE I 123 profile page.

The generic ingredient in SODIUM IODIDE I 123 is sodium iodide i-123. There are one thousand three hundred and ninety-two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the sodium iodide i-123 profile page.

Summary for NDA: 018671

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 018671

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SODIUM IODIDE I 123
sodium iodide i-123
CAPSULE;ORAL 018671 NDA Cardinal Health 418, Inc 48815-1001 48815-1001-1 1 VIAL, PLASTIC in 1 CAN (48815-1001-1) > 1 CAPSULE, GELATIN COATED in 1 VIAL, PLASTIC
SODIUM IODIDE I 123
sodium iodide i-123
CAPSULE;ORAL 018671 NDA Cardinal Health 418, Inc 48815-1001 48815-1001-5 1 VIAL, PLASTIC in 1 CAN (48815-1001-5) > 5 CAPSULE, GELATIN COATED in 1 VIAL, PLASTIC

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength100uCi
Approval Date:May 27, 1982TE:AARLD:Yes

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength200uCi
Approval Date:May 27, 1982TE:AARLD:Yes

Summary for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE;ORALStrength400uCi
Approval Date:May 27, 1982TE:RLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Cipla
US Department of Justice
Covington
AstraZeneca
Julphar
Deloitte
QuintilesIMS
Cerilliant
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot